ARRA Investments in Lupus
Public Health Burden
Lupus, a disabling and life-threatening autoimmune disease, affects more than 1.5 million Americans, 90 percent of whom are women. Lupus is 2-3 times more common among African Americans, Native Americans, Hispanics, and Asians, than among Caucasians.
No new treatments have been approved for lupus in forty years. A variety of ARRA funded grants are exploring new targets to treat this condition. A few include:
Advancing our understanding of immune system regulation in lupus, which could guide development of treatment approaches.
Defining how a particular therapy restores normal regulation of the immune system in lupus and how it may be applied to other autoimmune diseases
Seeking to understand the factors produced by lymphocytes that lead to the production of pathogenic autoantibodies. This project may reveal new therapeutic targets against lupus.
Scientists have made progress in defining the association between human leukocyte antigen region genes, or genetic markers, and immune-mediated diseases. ARRA-funded projects are exploring genetic risk factors that are specific for lupus.
One project aims to identify genetic risk factors in subjects with autoimmunity, including lupus, as well as the identification of gene-environment interactions that are involved in human autoimmune disorders.
Another project seeks to discover and validate biomarkers of lupus, which could benefit existing patients by providing more accurate diagnoses that may suggest more effective treatment.
Lupus disproportionately affects woman. A number of ARRA funded grants are focused on understanding the basis for this gender difference.
One project seeks to provide critical insight into hormonal regulation of lupus disease development and to identify novel therapeutic approaches for lupus patients.
Another project seeks to increase understanding of the molecular basis of sex bias in lupus disease and could potentially lead to better diagnostic tools, disease monitoring, and treatments.
Developing a greater understanding of the fundamental biologic principles involved in lupus is critical for diagnosing, treating and preventing this disease. ARRA supported work in this area includes:
Improving the understanding of the causes of neuropsychiatric syndromes in systemic lupus.
Investigating the natural mechanisms that maintain self-tolerance and respond to infection and inflammation. This may offer insights into how autoimmune diseases, such as lupus, develop.
Advancing understanding of fundamental immune mechanisms, which could lead to improvements in the treatment of autoimmune diseases.
Studying the balance that must be maintained by the immune system between recognition of infection and prevention of autoimmunity
-- Protein Kinase A-Dependent Regulation of T cell Accumulation in Lupus -- Khan, Islam
-- Genetic, Viral and Immunlogic Studies in New Zealand Mice -- Datta, Syamal
-- Suppression of Pathogenic Autoantibodies in Lupus by Inhibition of AID -- Mountz, John
-- Mapping Autoimmune Phenotypes in Multiplex Families -- Gregersen, Peter
-- Profiling Epigenetic Biomarkers for the Study and Treatment of Lupus -- Liu, Chih
-- Progesterone and Estrogen Differentially Regulate DC Functions in Lupus Autoimmunity -- Hughes, Grant
-- The Role of Sex in Self Antigen Generation in SLE -- Pisetsky, David
-- Anti-NMDA Receptor Antibodies in Brain Dysfunction: Lessons from Lupus -- Diamond, Betty
-- A Model System for the Study of Human B-cell Tolerance -- Sanz, Ignacio
-- Cell Death and Antibody-Mediated Protection from Autoimmunity -- Silverman, Gregg J
-- The Cell Biology of Toll-Like Receptor 9: A Mechanism to Prevent Autoimmunity -- Barton, Gregory
Page Last Updated on June 30, 2018
Turning Discovery Into Health